[go: up one dir, main page]

BR112016003196A2 - método para separar anticorpos biespecíficos - Google Patents

método para separar anticorpos biespecíficos

Info

Publication number
BR112016003196A2
BR112016003196A2 BR112016003196A BR112016003196A BR112016003196A2 BR 112016003196 A2 BR112016003196 A2 BR 112016003196A2 BR 112016003196 A BR112016003196 A BR 112016003196A BR 112016003196 A BR112016003196 A BR 112016003196A BR 112016003196 A2 BR112016003196 A2 BR 112016003196A2
Authority
BR
Brazil
Prior art keywords
bispecific antibodies
separating bispecific
separating
antibodies
bispecific
Prior art date
Application number
BR112016003196A
Other languages
English (en)
Other versions
BR112016003196A8 (pt
Inventor
Sabine Bertl
Harald Duerr
Andreas Schaubmar
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112016003196A2 publication Critical patent/BR112016003196A2/pt
Publication of BR112016003196A8 publication Critical patent/BR112016003196A8/pt

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/362—Cation-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
BR112016003196A 2013-08-19 2014-08-18 método para separar anticorpos biespecíficos BR112016003196A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13180912 2013-08-19
PCT/EP2014/067552 WO2015024896A1 (en) 2013-08-19 2014-08-18 Separation of bispecific antibodies and bispecific antibody production side products using hydroxyapatite chromatography

Publications (2)

Publication Number Publication Date
BR112016003196A2 true BR112016003196A2 (pt) 2017-08-01
BR112016003196A8 BR112016003196A8 (pt) 2020-02-04

Family

ID=48985686

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016003196A BR112016003196A8 (pt) 2013-08-19 2014-08-18 método para separar anticorpos biespecíficos

Country Status (11)

Country Link
US (1) US10316059B2 (pt)
EP (1) EP3036253B1 (pt)
JP (1) JP6560673B2 (pt)
KR (1) KR20160044023A (pt)
CN (2) CN118271429A (pt)
BR (1) BR112016003196A8 (pt)
CA (1) CA2919174A1 (pt)
HK (1) HK1223108A1 (pt)
MX (1) MX2016001601A (pt)
RU (1) RU2652911C2 (pt)
WO (1) WO2015024896A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016232349B2 (en) * 2015-03-13 2022-01-20 Novimmune Sa Methods of purifying bispecific antibodies
MA56416A (fr) * 2015-05-12 2022-05-04 Regeneron Pharma Détermination de la pureté de protéines multimériques
BR112018003127A2 (pt) * 2015-08-20 2018-09-25 Genentech Inc purificação de fkpa e usos do mesmo para produzir polipeptídeos recombinantes
JP7084301B2 (ja) * 2015-08-21 2022-06-14 エフ．ホフマン－ラ ロシュ アーゲー 低伝導率洗浄緩衝液を用いたアフィニティークロマトグラフィー精製方法
WO2017032686A1 (en) 2015-08-21 2017-03-02 F. Hoffmann-La Roche Ag Method for the reduction of host cell proteins in affinity chromatography
US11186858B1 (en) 2016-03-15 2021-11-30 Fresenius Kabi Deutschland Gmbh Methods for increasing biosimilarity
HUE068564T2 (hu) * 2016-06-17 2025-01-28 Hoffmann La Roche Multispecifikus antitestek tisztítása
WO2018038469A1 (ko) * 2016-08-20 2018-03-01 (주)아이벤트러스 목적하는 이중특이성 항체의 선택적 생산 확인 방법
CN106800599B (zh) * 2016-12-05 2021-03-23 中国人民解放军第二军医大学 抗人EGFR和Notch多特异性抗体、其制备方法及用途
AU2018303254B2 (en) 2017-07-21 2025-05-29 Novimmune Sa Generating multispecific antibody mixtures and methods of uses thereof
US11945839B2 (en) 2017-12-22 2024-04-02 Hoffmann-La Roche Inc. Depletion of light chain mispaired antibody variants by hydrophobic interaction chromatography
MX2020008931A (es) * 2018-02-27 2020-10-01 Pfizer Purificacion de anticuerpos.
GB201805142D0 (en) * 2018-03-29 2018-05-16 Ge Healthcare Bioprocess R&D Ab Separation method
CN109517043B (zh) * 2018-11-23 2022-06-14 艾美诚信生物制药有限公司 一种原核表达重组轮状病毒抗原p2-vp8的纯化方法
AU2020221649B2 (en) * 2019-02-14 2025-03-27 Merus N.V. Producing compositions comprising two or more antibodies.
CN114409798A (zh) * 2019-02-14 2022-04-29 美勒斯公司 制备包含两种或更多种抗体的组合物
CN113281430A (zh) * 2021-05-11 2021-08-20 苏州君盟生物医药科技有限公司 一种双特异性抗体的分离鉴定方法
CN116769044A (zh) * 2023-07-11 2023-09-19 康日百奥生物科技(苏州)有限公司 抗cd3和cd19双特异性抗体蛋白及其层析纯化方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2275431A3 (en) 2008-01-18 2011-05-25 Bio-Rad Laboratories, Inc. Enhanced fractionation of phosphorylated and nonphosphorylated biomolecules by apatite chromotography
MX2011009362A (es) * 2009-03-05 2011-09-26 Abbott Lab Proteinas de union a il-17.
AR080794A1 (es) * 2010-03-26 2012-05-09 Hoffmann La Roche Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
TW201138821A (en) * 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
US8895707B2 (en) * 2010-08-18 2014-11-25 Bio-Rad Laboratories, Inc. Elution of proteins from hydroxyapatite resins without resin deterioration
SG193378A1 (en) * 2011-03-16 2013-10-30 Hoffmann La Roche Ion exchange chromatography with improved selectivity for the separation of polypeptide monomers, aggregates and fragments by modulation of the mobile phase
CA2853011C (en) * 2011-10-19 2022-09-06 Novimmune S.A. Methods of purifying antibodies

Also Published As

Publication number Publication date
MX2016001601A (es) 2016-05-02
BR112016003196A8 (pt) 2020-02-04
US20160376304A1 (en) 2016-12-29
WO2015024896A1 (en) 2015-02-26
HK1223108A1 (zh) 2017-07-21
CN105473612A (zh) 2016-04-06
JP2016528268A (ja) 2016-09-15
RU2016109322A (ru) 2017-09-28
RU2652911C2 (ru) 2018-05-03
EP3036253A1 (en) 2016-06-29
CA2919174A1 (en) 2015-02-26
CN118271429A (zh) 2024-07-02
JP6560673B2 (ja) 2019-08-14
US10316059B2 (en) 2019-06-11
EP3036253B1 (en) 2020-09-23
KR20160044023A (ko) 2016-04-22

Similar Documents

Publication Publication Date Title
BR112016003196A2 (pt) método para separar anticorpos biespecíficos
PT3004163T (pt) Método para purificação de anticorpo
FI20135292L (fi) Menetelmä kartongin valmistamiseksi
ZA201506568B (en) Anti-tnf-anti-il-17 bispecific antibodies
CL2015002829A1 (es) Anticuerpos biespecíficos específicos para fap y dr5, anticuerpos específicos para dr5 y métodos de utilización
EP3083682C0 (en) DOUBLE SPECIFICITY ANTIBODIES
DK3336106T3 (da) Anti-fcrh5-antistoffer
DK3708583T3 (da) Ikke-fucosylerede anti-fgfr2iiib-antistoffer
FI20135770L (fi) Prosessi hiilivetyjen valmistamiseksi
FI20136031A7 (fi) Prosessi hiilivetyjen valmistamiseksi
PT3036292T (pt) Processo para a produção de polimerizados em emulsão
IL240753A0 (en) Antibody purification methods
DK3068800T3 (da) FcRn-specifikke antistoffer
DK2943261T3 (da) Flertrins-separationsfremgangsmåde
BR112016027652A2 (pt) Método para produzir tiametoxam
IL239689A0 (en) A method for producing antibodies
BR112015021083A2 (pt) método
EP2952895A4 (en) PROCESS FOR PRODUCING A MARKED ANTIBODY
DK3065774T3 (da) Anti-CCL17-antistoffer
BR112015029076A2 (pt) método
FI20135361L (fi) Analyyttinen menetelmä
IL241779A0 (en) Method for protein production
DK3042205T3 (da) Fremgangsmåde til forbedring af antistofstabilitet
BR112016012168A2 (pt) Método para produzir macarrões instantâneos
GB201301384D0 (en) Method for antibody production

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements